Moreover, since JAK2 appears to be not involved in type I or type II interferon-signaling, selective Jak-2 specific inhibitors may provide a better outcome for suppressing IL-6-GM-CSF-signaling-in COVID-19-associated cytokine storms. The gene discussed is IL6; the disease is COVID-19.